McKesson Corporation vs Under Armour Inc Class A — how do they compare? McKesson Corporation trades at $825.74 (market cap $97.35B), while Under Armour Inc Class A trades at $7.32 (market cap $3.07B). The key difference: McKesson Corporation is far larger — about 31.7× Under Armour Inc Class A's market cap, and McKesson Corporation pays a 0.39% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| MCK | UAA | |
|---|---|---|
Market Cap | $97.35B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $8.14 |
52-Week Low | $659.01 | $4.17 |
Enterprise Value | $101.98B | $4.70B |
Dividend Yield | 0.39% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Under Armour (UAA) trades at $7.28, down 2.02% amid mixed signals. The stock shows technical bullish momentum with strong moving average support, but faces fundamental challenges including a net loss of $201.27 million in 2025 and negative profit margins. Recent earnings showed Q4 2025 beat expectations but Q1 2026 missed, while the company maintains international growth momentum despite North American weakness.
The outlook remains cautious with analyst consensus price target of $5.96 below current levels. Investment opportunity exists in international expansion and DTC growth, but risks include persistent North American weakness, margin pressure, and negative cash flow trends that could pressure shareholder value in the near term.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →